The United Arab Emirates has launched a one-month public consultation on proposed regulations for the transplantation and implantation of non-human organs and tissues into humans, following recent amendments to its organ donation and transplantation laws. The consultation aims to gather input from relevant stakeholders on how to govern this emerging medical practice safely and effectively.
The regulatory changes, introduced in a decree-law amendment issued on December 10, 2025, expanded the UAE’s existing legislative framework to include non-human organs and tissues—specifically those derived from animals and manufactured sources—as potential transplant materials. Prior legislation had been limited to human organs and tissues only. The amended law sets out the foundation for detailed controls and standards related to the use of these non-human biological materials.
The government’s consultation, hosted on the UAE Legislation platform’s Community Engagement Unit, invites healthcare providers, legal experts, researchers, and other concerned parties to provide their perspectives on multiple aspects of the proposed rules. The feedback form addresses the importance of a clear legislative framework, the benefits of regulation, necessary safety controls and standards, risks involved, potential challenges, and measures to support implementation within the UAE’s healthcare system.
Among the safeguards incorporated in the amended law, the transplantation of non-human organs or tissues is permitted only when it represents the best medical option for the patient’s condition. The removal of animal organs for transplantation requires a license from the Ministry of Health and Prevention or the relevant authorities. Health facilities and manufacturers must secure appropriate permits and conduct rigorous clinical and laboratory testing to confirm safety and efficacy.
Physicians involved in such procedures are required to ensure biological compatibility, inform patients or their legal representatives about all known and potential health risks, and obtain written informed consent. Penalties for violations of the new controls can include fines ranging from 100,000 to 2 million UAE dirhams and possible imprisonment. These penalties apply to health facilities, manufacturers, and medical specialists who breach the law.
The UAE’s regulatory update aligns with global developments in alternative organ transplantation technologies, including xenotransplantation and bioengineered organs. The World Health Organization has highlighted advances in gene editing and related technologies that have enabled clinical trials involving the transplantation of animal organs into human subjects, while emphasizing the need for robust regulatory oversight.
A WHO report from December 2025 noted ongoing consultations regarding the regulatory landscape for xenotransplantation and stressed that although research is advancing, animal-derived and bioengineered products are not yet a complete substitute for human organ donations.
The UAE’s consultation period provides an opportunity for stakeholders to shape the nation’s approach to these innovative medical practices, balancing scientific progress with patient safety, ethical standards, and compliance requirements.